NPM1-mutated AML prognosis was refined using a new genetic model integrating co-mutations, improving risk classification and ...
In June 2024, multiple state regulators took joint action against Plutus Financial, Inc (Abra) ordering Abra to cease and desist certain operations in the U.S. and reimburse customers of virtual ...
Revumenib demonstrates significant efficacy in R/R AML with NPM1m, KMT2Ar, and NUP98r, showing high response rates and tolerability. The AUGMENT-101 study reports a 26% CR/CRh rate in NPM1-mutated AML ...
A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...
Secondary acute myeloid leukemia (AML) is a blood cancer that arises from other blood disorders or previous cancer treatment. Those with secondary AML tend to have a less favorable outlook than those ...
IN8bio, Inc. announced that 100% of acute myeloid leukemia (AML) patients treated with its allogeneic gamma-delta T cell therapy, INB-100, remain in complete remission (CR) with a median follow-up of ...
Acute myeloid leukemia (AML) cells under the microscope, in purple. There is a serious need for finding better ways to treat AML that comes back after initial treatment. Chimeric antigen receptor (CAR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results